Developing disease-modifying neuropathic pain therapies that reverse pathophysiology, relieve chronic pain, and potentially cure it

Targeting Pain at Its Source

  • Releviate’s therapy inactivates secreted Matrix Metalloproteases that cause chronic pain.

  • Approach is very similar to the Abbvie’s Humira: inactivating the master-switch (in the case of Humira – TNF), which affects multiple pathophysiological pathways.

  • Instead of masking or blocking the pain pathway, Releviate’s therapy treats the underlying pathology resulting in painful sensation. 

The Cost of Pain

Chronic pain is the largest indication in the world and the #1 reason for doctors visits in the U.S. Approximately 100 million adults in the U.S. are affected by chronic pain each year. The annual total cost of pain – including direct costs, decreased wages, and lost productivity – eclipses that of any other condition.

Diabetes $170 Billion
Cancer $250 Billion
Cardiovascular Disease $270 Billion
Chronic Pain Over $600 Billion

A New Discovery

Researchers are aggressively studying the potential role MMPs play in the progression of different oncological and autoimmune diseases. However, only recently Releviate basic, translational and clinical scientists determined the role of some MMPs in pain.

Read More

Addressing Unmet Needs in Chronic Pain

There is significant pre-clinical evidence that Releviate’s therapy is disease-modifying, reversing underlying pathophysiology leading to the neuropathic pain onset and maintenance. Based on this new insight into mechanisms of neuropathic pain, a Releviate-associated team developed patented, human monoclonal antibodies that inactivate MMP-9 and MMP-14.

Releviate holds an exclusive license for the technology. READ MORE

Releviate is currently initiating regulatory activities leading to Phase IIa clinical trials in small fiber neuropathy (SFN) patients to assess the safety and efficacy of Releviate’s therapy.


Find Out More